VICTORIA, British Columbia–(BUSINESS WIRE)–
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company has established its U.S. commercial center of operations in Rockville, Maryland. The new site will support Aurinia’s plans for growth as it prepares for the potential approval and launch of voclosporin for the treatment of lupus nephritis in 2021.
{iframe}https://biobuzz.inloop.com/en/article/78932/aurinia-pharmaceuticals-establishes-u-s{/iframe}